Travere Therapeutics, Inc. (TVTX) - Stock Analysis
Last updated: Apr 11, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠High operating spend ⢠Recent EBITDA rebound TVTX has strong liquidity and gross margins with recent quarter-level operating improvement but is weighed down by very high R&D/SG&A, heavy leverage and FY losses despite lofty market multiples.
Price Behavior
Key Price Behavior Insights: ⢠Mild uptrend ⢠Resistance cap ⢠Volatility spike Support Level: $26.8â$27.3 Resistance Level: $31.6â$31.8 TVTX shows a modest short-term bullish biasâlast month SMA ~$28.80 with the $28.96 close slightly above, recovery from March lows (~$26.79) and ~5% rise since mid-March offset by a resistance cluster near $31.6â31.8 and a sharp one-day drop raising short-term volatility. â
Sentiment & News
Key News Insights: ⢠Large institutional cut ⢠CEO and director sales ⢠Narrow price range Insiders and Aberdeen sharply trimmed positions in Travere (TVTX) in early April 2026âmultiple sizable sales within a tight $30.93â$33 range, indicating concentrated disposition without accompanying corporate news. #insider-sellingâ
AI Summary
TVTX has shifted from a development play to a binary, commercially-driven story where the PDUFA decision and Filspari launch execution will largely determine whether high-margin sales convert into durable profitability or trigger sharp cash/valuation stress. Positioning should be event-driven: favor exposure only with a positive PDUFA and clear post-approval uptake metrics (sustained quarter-over-quarter U.S. net sales growth and contained gross-to-net â¤20%); otherwise hedge or reduce exposure given high leverage and execution risk.
Description
Travere Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for rare diseases. Its marketed portfolio includes treatments for bile acid disorders and a drug for cystinuria, while its pipeline comprises a Phase III program for kidney diseases and an investigational enzyme-replacement candidate for classical homocystinuria. The company conducts partnered research with the NIH and patient organizations on rare genetic conditions, was renamed from Retrophin in 2020, and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | TVTX | Travere Therapeutics, Inc. | Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally. | Closed | -2.0% |